However, I gather from this review in Nature of a new book Mescaline: A Global History of the First Psychedelic, that Huxley was way over-selling the drug's positives.
For one thing, I didn't realise (or perhaps had forgotten?) that (like ayahuasca in South America) it makes the average user pretty sick at first:
The powers of endurance needed to take the drug became more widely known: it induces hours of nausea and often vomiting before the hallucinations begin. (In contrast to alcohol, Jay notes, mescaline gives you the hangover first.)But more importantly, while I seem to recall that Huxley gave the impression that the use of mescaline (outside of Native American culture) and exploring its effects was something pretty new, the book tells a story of experimentation with it going back much further:
In traditional ceremonial use, the hallucination phase has been reported as consistently transporting. But outside these cultures, those eager to experiment have had disconcertingly unpredictable experiences. In 1887, Texan physician John Raleigh Briggs was the first to describe in a medical journal his own, rather violent, symptoms — including a racing heart and difficulties breathing — after eating a small part of a ‘button’, or dried crown, of a peyote cactus. The pharmaceutical company Parke–Davis in Detroit, Michigan, which had been investigating botanical sources of potential drugs from South America and elsewhere, took note. The company was seeking an alternative to cocaine, whose addictive properties had become apparent; it began offering peyote tincture as a respiratory stimulant and heart tonic in 1893.This really puts Huxley's praise of the drug in a different light, doesn't it? Again, I am going by memory here, but I think he gave the impression that his personal investigation of the effects of the drug were somewhat ground breaking, but it had been very well investigated before and known to be very unreliable in effect. (I recall he did acknowledge once having a trip which at least verged towards turning into a hellish one. Perhaps his book was influential in promoting the dangerous idea that, if you start out in the right frame of mind, you can be pretty sure your trip will be good.)
A flurry of scientific trials began. There was scant regard for ethics and safety — for the scientists, who frequently tested the mescaline themselves, or for test subjects. In 1895, two reports demonstrating the drug’s unpredictability came out of what is now the George Washington University in Washington DC. In one, a young, unnamed chemist chewed peyote buttons and then noted down his symptoms: nausea followed by pleasant visions over which he had some control, then depression and insomnia for 18 hours. In the other, two scientists observed the drug’s effects on a 24-year-old man, who became deluded and paranoid.
In New York City, pharmacologists Alwyn Knauer and William Maloney carried out a more extensive trial, including 23 people, in 1913. They hoped that mescaline, as a hallucinogen, might provide insight into the psychotic phenomena associated with schizophrenia. It didn’t. The pair diligently recorded participants’ running commentaries on their hallucinations, but found no common characteristics. (In later studies, people with schizophrenia could easily tell the difference between their own hallucinations and those induced by the drug.)
The pace of trials picked up after synthetic mescaline became available. Chemist Ernst Späth at the University of Vienna was first to synthesize it, in 1919, and the German pharmaceutical company Merck marketed it the following year. Yet trial outcomes did not become more reliable or illuminating. Over the next couple of decades, theories that mescaline might reveal the biological basis of schizophrenia or help to cure other psychological disorders were serially dashed.
It's another lesson in not taking pretty sensationalist claims all that seriously until you know more of the background of the topic.
No comments:
Post a Comment